Market Place
Sourcing Support
Neurogene Announces Closing of Merger with Neoleukin Therapeutics
19 Dec 2023 //
BUSINESSWIRE
Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
14 Dec 2023 //
GLOBENEWSWIRE
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
22 Sep 2023 //
GLOBENEWSWIRE
Neurogene inks Neoleukin reverse merger to fund gene therapies
18 Jul 2023 //
FIERCE BIOTECH
Neoleukin sends 70% of staff packing as IL-2 biotech searches for sale
10 Mar 2023 //
ENDPTS
Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at (ASH)
12 Dec 2022 //
GLOBENEWSWIRE
Adamis, Harpoon, Neoleukin and Tricida grow biotech layoff wave
15 Nov 2022 //
FIERCEBIOTECH
Neoleukin Therapeutics Announces 3Q 2022 Financial Results and Corporate Update
14 Nov 2022 //
GLOBENEWSWIRE
Neoleukin Therapeutics Announces Oral Presentation at 64th (ASH) Annual Meeting
03 Nov 2022 //
GLOBENEWSWIRE
Neoleukin Therapeutics Announces Second Quarter 2022 Financial Results
09 Aug 2022 //
GLOBENEWSWIRE
Neoleukin Tx to Present at Canaccord Genuity 42nd Annual Growth Conference
03 Aug 2022 //
GLOBENEWSWIRE
Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results
27 Jul 2022 //
GLOBENEWSWIRE
Neoleukin Treats First Patient in Combination Arm of PI Trial Evaluating NL-201
16 May 2022 //
GLOBENEWSWIRE
Neoleukin Therapeutics Announces First Quarter 2022 Financial Results
09 May 2022 //
GLOBENEWSWIRE
Neoleukin Therapeutics to Present at Upcoming Investor Conferences
05 May 2022 //
GLOBENEWSWIRE
Neoleukin Shows Preclinical Data for NL-201 at AACR
13 Apr 2022 //
GLOBENEWSWIRE
Neoleukin Tx to Present at Canaccord Genuity Horizons in Oncology Conference
07 Apr 2022 //
GLOBENEWSWIRE
Neoleukin Tx says Appointment of Donna Cochener as General Counsel
15 Mar 2022 //
GLOBENEWSWIRE
Neoleukin Tx says Multiple Presentations at AACR
08 Mar 2022 //
GLOBENEWSWIRE
Neoleukin Tx Announces Year End 2021 Financial Results and Corporate Update
01 Mar 2022 //
GLOBENEWSWIRE
Neoleukin Therapeutics to Host 2021 Financial Results Conference Call
22 Feb 2022 //
GLOBENEWSWIRE
Neoleukin Tx to Present at Guggenheim Healthcare Talks 2022 Oncology Conference
03 Feb 2022 //
GLOBENEWSWIRE
Neoleukin Tx Presenting at H.C. Wainwright BIOCONNECT Virtual Conference
10 Jan 2022 //
GLOBENEWSWIRE
Neoleukin Therapeutics Presents NL-201 Preclinical Data at SITC 2021
12 Nov 2021 //
GLOBENEWSWIRE
Neoleukin Therapeutics Announces Multiple Abstracts Accepted for Presentation
01 Oct 2021 //
GLOBENEWSWIRE
Neoleukin Therapeutics Announces Oral Presentation at IDWeek 2021 of Data
29 Sep 2021 //
GLOBENEWSWIRE
Neoleukin Announces Appointment of Bill Arthur as VP and Head of Research
09 Sep 2021 //
GLOBENEWSWIRE
Neoleukin Therapeutics Announces Second Quarter 2021 Financial Results
05 Aug 2021 //
GLOBENEWSWIRE
Neoleukin Announces Clearance to Proceed with NL-201
26 Apr 2021 //
GLOBENEWSWIRE
Neoleukin Receives Clinical Hold Letter from U.S. FDA Related to CMC Assay
08 Jan 2021 //
GLOBENEWSWIRE
Neoleukin Therapeutics Announces Submission of Investigational NDA for NL-201
10 Dec 2020 //
GLOBENEWSWIRE
Neoleukin Presents Preclinical Combination Data for NL-201
10 Nov 2020 //
GLOBENEWSWIRE
Neoleukin Announces Publication in Science of De Novo Protein Decoys
05 Nov 2020 //
GLOBENEWSWIRE
Neoleukin Therapeutics Announces Abstract Accepted for Presentation
14 Oct 2020 //
GLOBENEWSWIRE
Neoleukin Therapeutics Presents Preclinical Data for NL-201 and De Novo Protein
22 Jun 2020 //
GLOBENEWSWIRE
Neoleukin Therapeutics Provides Update on COVID-19 Impact on Corporate
09 Apr 2020 //
GLOBBENEWSWIRE
